Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Quinsair for treatment of cystic fibrosis to Commercially Launch in Canada in H2 of 2016

Source Link:: http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID=957291

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

RPTP

100%

HZNP

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Quinsair (nebulized levofloxacin) is expected to launch in both Europe and Canada in 2016. Quinsair is designed for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis. Raptor Pharma plans to discuss potential approval of the same indication in the US in 2016.

http://ir.raptorphar...

Additional Relevant Details In April, Raptor launched QUINSAIR in Germany and Denmark for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis, and to date, QUINSAIR has become available for reimbursement in several territories in the EU and Raptor is actively expanding into new countries.Raptor anticipates launching QUINSAIR in Canada for the same indication, for which it has received marketing approval, in the second half of 2016.

http://ir.raptorphar...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 22, 2016

Occurred Source:

https://globenewswire.com/news-release/2016/12/22/901175/0/en/Horizon-Pharma-plc-Announces-Availability-of-QUINSAIR-levofloxacin-inhalation-solution-in-Canada-for-the-Treatment-of-Specific-Lung-Infections-in-Adults-with-Cystic-Fibrosis.html

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Quinsair, Nebulized Levofloxacin, Chronic Pulmonary Infections, Pseudomonas Aeruginosa, Cystic Fibrosis